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Structured Abstract 
Word count abstract: 248 
Background: 
It is recommended to vaccinate pregnant women against influenza. A possibly impact on the 
immune expression of the fetus has never been studied.  
We aim to study the immune signature in the upper airways and the incidence of infections in 
neonates born to mothers receiving Influenza A(H1N1)pnd09 vaccination during pregnancy.  
Methods: 
156 women from the unselected Copenhagen Prospective Study on Asthma in Childhood 
(COPSAC2010) received Influenza A(H1N1)pnd09-vaccination during the 2009 pandemic. 51 
mothers received the vaccine during pregnancy and 105 after pregnancy. 332 neonates of non-
vaccinated mothers were included as secondary controls. Nasal mucosal lining fluid was sampled in 
488 neonates and assessed for IL-12p70, IP-10, IFN-γ, TNF-α, MIP-1β, MCP-1, MCP-4, IL-4, IL-
5, IL-13, eotaxin-1, eotaxin-3, TARC , MDC, IL-17, IL-1β, IL-8, TGF-β1, IL-10 and IL-2. 
Infections were monitored the first year of life by daily diary cards and clinical controls. 
Results: 
Neonates of mothers vaccinated during pregnancy had significant up-regulation of TGF-β1 
(ratio=1.52 [1.22-1.90], p=0.0002), and corresponding down regulation (p<0.05) of IL-12p70, IFN-
γ, IL-5, eotaxin-1, TARC, MDC, IL-8 in comparison to those vaccinated after pregnancy. The lag-
time from vaccination during pregnancy to assessment of the immune signature showed significant 
and positive association to up-regulation of TGF-β1 levels (P= 0.0003) and significant negative 
association to other mediators. The incidence of infections in early infancy did not differ between 
the study groups. 
Conclusion: 
Influenza A(H1N1)pnd09 vaccination during pregnancy up-regulates TGF-β1 and down-regulates 
key mediators of the protective immunity, but the rate of clinical infections was not detectably 
affected 
 
 
Abstract
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
4 
 
Unstructured Abstract 
In this paper we aim to study the immune signature of the upper airways and the incidence of 
infections in neonates born to mothers receiving Influenza A(H1N1)pnd09 vaccination during 
pregnancy.  We find that vaccination during pregnancy up-regulates TGF-β1 and down-regulates 
key mediators of the protective immunity, we find no influence on clinical infections.  
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Introduction 
Influenza vaccination of pregnant women is generally recommended for the protection of both 
women and children,
1
 in particular during the recent Influenza A(H1N1)pnd09 (H1N1pnd09) 
pandemic in 2009.
2,3
 
The outcome of influenza infection during pregnancy is more severe during seasonal influenza 
epidemics,
4–6
 and even graver during influenza pandemics.
7–9
 Accordingly, the hospital admission 
and mortality rates were higher in pregnant women with influenza than in the general population 
during the 2009 pandemic,
10–12
 with increased rates of stillbirth, perinatal and neonatal mortality in 
infected pregnant women.
13
 
Influenza is also a major cause of morbidity and hospitalization in infants younger than six 
months.
14–16
  In particular the H1N1pnd09 pandemic caused more severe disease in the neonates 
and young infants than in older children, all unprotected from passive immunity to this novel 
virus.
17
 
No vaccination is approved for infants younger than six months.
18,19
 Therefore influenza 
vaccination during pregnancy has been proposed as a safe way to protect infants,
1,5,20
 presumably 
by cocooning
21,22
 and from antibodies transmitted from the mother.
1,15,23
 Yet the evidence is 
ambiguous as to the protective efficacy in the infants of vaccines given during pregnancy.
24
  
It is well known that the maternal millieu during pregnancy affects the fetal immune competence. 
25–27
  While there is no published evidence on the possible effect of vaccination during pregnancy 
on the neonatal immune status, influenza vaccination is generally considered safe for the pregnant 
mother and the fetus. 
Therefore, to examine the in vivo immune signature at the upper airways, we analyzed the cytokine 
and chemokine signature of the upper airway mucosa in neonates 4 weeks after birth
26,28,29
 and 
monitored the incidence of infections in the first year of life in infants of mothers receiving 
H1N1pnd09-vaccination during pregnancy versus neonates of mothers not vaccinated during 
pregnancy.
30
 Furthermore we examined whether the time of vaccination during pregnancy was of 
importance to the impact of the vaccination on the cytokine and chemokine signature.   
Manuscript
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Methods 
Design of the COPSAC2010 Cohort Study 
The novel COPSAC2010 cohort is an ongoing unselected prospective clinical study of 743 pregnant 
women and their 700 children. The pregnant women were recruited during gestational week 20-24 
in 2009-2010.
26
 Key exclusion criteria were; chronic endocrine-, nephro- or cardiac diseases. The 
neonates were enrolled at one week of age excluding infants with severe congenital abnormality.
26
  
Information on confounders and baseline data were collected by structured clinical interviews at the 
parents’ first visit to the COPSAC research clinic during gestational week 24 and 36, and again at 
one and four weeks after birth.  
The families were seen at the COPSAC research clinic at age one week, one month, three months, 
six months and at six monthly intervals hereafter for close clinical follow-up.  
Daily diary cards were used to monitor infections in the infants in the first year of life. Infections 
were categorized as common cold, pharyngitis, otitis, pneumonia, fever and gastro-intestinal 
infection. Parents were instructed how to fill in the diaries at study inclusion, and the diary cards 
were reviewed with the research doctor at each visit to clarify symptom definitions. Additionally, 
the research doctor interviewed the parents about other illness and any health care contacts outside 
the research clinic.    
The database was double-checked against source data by and was subsequently locked. Data 
validity was assured by compliance with Good Clinical Practice guidelines and quality control 
procedures. An audit trail was done routinely. 
All bio-sampling, clinical assessments and data collection were performed by a medical doctor with 
pediatric training and captured in a dedicated database on a novel SQS server.  
Design of the Nested Influenza Vaccination Study  
Women participating in the COPSAC2010 cohort study were invited into a nested randomized trial of 
the safety and immunogenicity of a standard dose of 7.5µg of the monovalent influenza 
A/California/2009 (H1N1pnd09) surface-antigen MF59-adjuvanted vaccine (Focetria®, Novartis). 
Details of the study  was recently reported.
30
 
The study was initiated November 2009 early in the H1N1pnd09 pandemic, i.e. in the middle of the 
cohort recruitment period allowing comparison of the vaccine effects in pregnant and post-partum 
women. The recruitment was hampered by two factors; primarily the Danish Health Authorities 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
7 
 
were ambiguous in their recommendations for vaccination of pregnant women  changing their 
recommendations during the pandemic. This ambivalence caused the women to doubt the necessity 
and safety of the offered vaccination. Secondly the clinical symptoms of the pandemic proved less 
serious than expected causing the women to reject the offer of receiving the vaccine.
30
 
Measurements of Airway Inflammatory Mediators in Upper Airway Mucosal Lining Fluid of 
Neonates 
Airway mucosal lining fluid was collected at four weeks of age with a pair of 3x15mm strips of 
filter paper (Accuwik Ultra, fibrous hydroxylated polyester sheets, cat no.SPR0730, Pall Life 
Sciences, UK) as previously described in detail.
28
  
The mucosal lining fluid was analyzed for levels of Interleukin (IL)-12p70, CXCL10 (IP-10), 
Interferon-gamma (IFN-γ), Tumor necrosis factor-alpha (TNF-α), CCL4 (MIP-1β), CCL2(MCP-1), 
CCL13 (MCP-4), IL-4, IL-5, IL-13, CCL11 (eotaxin-1), CCL26 (eotaxin-3), CCL17 (TARC ), 
CCL22 (MDC), IL-17, IL-1β, CXCL8 (IL-8), Transforming growth factor beta  (TGF-β1), IL-10 
and IL-2  as previously described in detail.
26,28
  
Covariates 
Covariates were decided a priori based on our previous analyses showing association between the 
airway immune signature of the neonates and maternal atopic disease
26
, older siblings in the house 
and airway colonization with pathogenic bacteria.
29
 Furthermore we adjusted for vaccination month 
because there is a seasonal bias in the data collection since vaccination of participants peaked 
around the start of the pandemic in the winter of 2009. 
Statistical analyses 
All mediator levels were log-transformed prior to analysis. The associations between 
cytokines/chemokines levels in the two vaccine groups and the associations to the time of 
vaccination were tested using generalized linear models (GLM), for unadjusted as well as adjusted 
analysis. Results are reported as ratios between mean values of cytokines and chemokines , in the 
upper airway mucosal lining fluid in neonates of mothers vaccinated during pregnancy compared to 
the control group(vaccinated after pregnancy)  with 95% confidence intervals in squared brackets.  
Baseline characteristics in the three groups were compared using Fisher’s exact test, Wilcoxon 
Rank sum test and one-way analysis of variance (Anova). 
The association between maternal vaccination and cumulative incidence of infections in the 
offspring throughout the first year of life was assessed by Quasi-Poisson regression estimating 
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Incidence Risk Ratios (IRR), adjusting for season of birth, older siblings, and maternal atopic 
disease. In the secondary analysis we further adjusted for participation in the randomized study. 
P-value≤0.05 is considered significant.   
The data processing was conducted using SAS version 9.2 (SAS Institute, Cary, NC). 
 
 
Results 
Baseline Characteristics: Vaccines and Mucosal Lining Fluid 
The study included 156 neonates of mothers participating in the randomized controlled trial of 
standard dose (7.5µg) of the H1N1pnd09 , MF59-adjuvanted vaccine (Focetria®, Novartis) 51 of 
the neonates  were born to mothers vaccinated during pregnancy and 105 were born to mothers 
vaccinated after pregnancy (Figure E1 in SDC).  
A secondary analysis compared children of mothers vaccinated during pregnancy with the children 
of 332  non-vaccinated mothers (Figure E1 in SDC). 
The median time from vaccination of the pregnant women to sampling of mucosal lining fluid was 
130 days (interquartile range, 95-146 days). The median age at mucosal lining fluid sampling in all 
neonates was 31 days (SD 5).  
The 51 women vaccinated during pregnancy and their children did not differ from the 105 women 
vaccinated after pregnancy and their children or the 332  non-vaccinated and their children with 
respect to gender; older siblings; gestational age at birth; birth weight; Apgar score one min after 
birth; baseline antibody titers; mode of delivery; mother’s age at birth; exposure to antibiotics, 
alcohol, and smoking during third trimester of pregnancy; paternal atopy; and household 
income(Table E1in SDC). 
Baseline Characteristics: Diary Cards 
152 out of 156 families (97%) included in the randomized study returned their diary cards for the 
first year of life. For the secondary analysis, 284 out of 332 non-vaccinated families (86%), returned 
their diary cards, yielding a total clinical follow up on 436 children (Figure E1in SDC). The mean 
number of infectious episodes pr. child was 8.2 (SD 4, range 0-24). Incidence of infections was 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
significantly associated to older siblings (IRR=1.11 [1.01-1.21], P=0.03) and birth season 
(IRR=0.88 [0.78-1.00], P=0.047 for children born in the Autumn compared to Summer, no 
significant difference between other seasons), but was not associated to maternal atopic disease or 
participation in the randomized study (Table 3). 
Mucosal Immune Profiles in Neonates of Mothers Vaccinated During versus After Pregnancy 
Neonates of mothers vaccinated during pregnancy showed a significant up-regulation of TGF-β1 
(ratio=1.52 [1.22-1.90], P=0.0002) compared to neonates of mothers vaccinated after pregnancy. 
Additionally, we found a significant (P≤0.05) down-regulation of IL-12p70, IFN-γ, IL-5, eotaxin-1, 
TARC, MDC, IL-8, and a non-significant trend of down-regulation of IL-1β (P=0.06) and IP-
10(P=0.10). Results are adjusted for season of birth, maternal atopy, older siblings, and airway 
colonization with pathogenic bacteria strains at sampling time. The adjustment induces greater 
effect size (estimates) and enhances the precision of the results. (Table 1 and Figure 1).  
Effect of Lag-Time from Vaccination to Sampling of Mucosal Lining Fluid 
The lag-time from vaccination to the assessment of the immune signature showed a significant and 
positive association to the up-regulation of TGF-β1 levels (P= 0.0003) (Figure 2), and a significant 
(P≤0.05) and negative association with IP-10, IFN-γ, IL-5, Eotaxin-3, TARC, MDC, IL-8 and IL-10 
in the mucosal lining fluid (Figure E2 and Table E2 in SDC).  
Mucosal Immune Profiles in Neonates of Mothers Vaccinated During Pregnancy versus non-
vaccinated Controls. 
Neonates of vaccinated mothers showed up-regulated TGF-β1 (ratio=1.32[1.11- 1.57], P=0.002) 
compared to neonates of non-vaccinated controls, a significant down-regulation of IFN-γ, IL-5, 
TARC, MDC (P≤0.05) and a non-significant trend of down-regulation of IL-12p70 (P=0.07), IL-4 
(P=0.08) and IL-13(P=0.07). Results are adjusted for participation in the randomized study, season 
of birth, maternal atopy, older siblings, and airway colonization with pathogenic bacteria strains at 
sampling time. (Table 2 and Figure 3). 
Clinical Infections in Children of Mothers Vaccinated During Pregnancy Versus After Pregnancy 
and  non-vaccinated Controls  
There was no significant difference in the incidence of infections during the first year of life in 
children of mothers vaccinated during pregnancy versus children of mothers vaccinated after 
pregnancy (aIRR=1.10 [0.89-1.36], P=0.37). Also there was no significant difference in incidence 
of infections in children of mothers vaccinated during pregnancy and non-vaccinated controls 
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(aIRR=0.99[0.84-1.18], P=0.95) (Table 3).  
 
Discussion 
Principle findings 
Vaccination with H1N1pnd09 vaccine during pregnancy induces alternations in the primary 
mucosal line of defense in the upper airways of newborn children. TGF-β1 is up-regulated and 
other key-mediators linked to protective immunity are down-regulated suggesting a compromised 
local immune defense. This effect is enhanced the earlier in the pregnancy the woman receives 
vaccination.  
We found no differences in the incidence of infections in the first year of life in the infants. 
Strengths and Limitations of the Study 
The H1N1pnd09 pandemic emerged in Denmark when the recruitment to our birth cohort was half 
completed. Therefore this “Experiment by Nature” allowed us to compare the effects of 
H1N1pnd09 vaccination in H1N1pnd09 -naïve women during pregnancy and post-partum. 
Furthermore the design of the study enables us to assess the effect of the vaccine given at different 
time points during pregnancy allowing us to demonstrate that the immune suppression, as 
determined by TGF-β1 levels, was significantly associated with the lag-time from vaccination to 
birth. 
It is a strength of this study that we see strong and similar response between all tested groups. 
Children of mothers vaccinated during pregnancy had up-regulated TGF-β1 compared to children 
of mothers receiving vaccine after pregnancy and children of non-vaccinated women. This was 
further confirmed by the significant association between the lag-time from vaccination in pregnancy 
to birth (sampling) and the TGF-β1 signal. Hereby the same conclusions are similar in 3 different 
models.  
It is a further strength of this study that it is nested in the well-established ongoing COPSAC birth 
cohort clinical research center. The setup of trained research doctors following standard operating 
procedures ensures consistency in the data material. The birth cohort study is designed as a clinical 
study with deep phenotyping of mother and child including comprehensive information’s obtained 
at repeated visits to the research unit. This allowed an extensive comparison of the case and control 
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cohorts of women together with detailed clinical follow-up of the children thereby increasing data 
validity, reducing the data variation and strengthening the effect estimates. 
The in vivo sampling of mucosal lining fluid has become a well validated method for non-invasive 
assessment of cytokines and chemokines in the airways of children
28,26,29,31
allowing us to measure 
undiluted samples directly from a target organ for respiratory disease, avoiding the dilemma of 
dilution accompanying nasal lavage models and intensified response found in challenge models.
32,33
 
It is a limitation to our study that we do not know the exact agent the children were infected with 
during their infections recoded in the daily diaries. One could speculate that we would find fewer 
cases of influenza in the children of vaccinated mothers and thereby comparably more cases of 
other infections.  
It is a limitation of this design that cases and controls did not receive the vaccinations  at the same 
time of year. Most women were vaccinated before the pandemic reached Denmark by the end of 
2009, but we continued vaccinating the pregnant women into early 2010 and therefore these (few) 
pregnant women in the study had a higher risk of contracting the natural infection. This we 
controlled for by the baseline IgG specific for H1N1pnd09, which did not differ between groups. 
Our findings cannot be uncritically extrapolated to other vaccines but must be limited to the 
H1N1pnd09 with MF59-adjuvanted vaccine we used. It is a limitation to the study that only 51 
women received the H1N1pnd09 vaccine during pregnancy. This limits the power to detect clinical 
effects on immune deviation from vaccination in pregnancy. 
Interpretation 
The children born of mothers receiving vaccination during pregnancy had significantly up-regulated 
TGF-β1 and down-regulation of Th1, Th2 and Th17 related mediators. TGF-β1 has specific effects 
associated with down-regulation of the transcription factors T-bet and GATA-3
34
, necessary for 
commitment of naïve CD4+ T-cells into Th1 and Th2 lineages, respectively. Moreover, both T-bet 
and GATA-3 activation are needed for maturation of cytotoxic NK cells, and NK functionality is 
thus also inhibited by TGF-β134. Since Th1 and NK cells are both sources of IFN-γ, and Th2 of IL-
5, IL-4 and IL-13, the lower levels of IFN-γ and IL-5 in neonates of vaccinated mothers could 
possibly be mediated via TGF-β1-induced suppression, but other mechanisms may also be in play. 
The pattern we found is similar to the general pattern seen during pregnancy, where it serves to 
protect the fetus from rejection by the mother’s immune response.35 Activation of the mother’s 
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adaptive immune reactions during pregnancy may in principle increase the risk of rejection of the 
fetus as reflected in the increased risk of abortion and preterm birth during Influenza infections .
9,13
 
Hence, it may be hypothesized that the boosted adaptive immune response in the vaccinated 
mothers is responsible for the down-regulation of the fetal immune system seen in our study. 
Down regulation of Th1 and Th17 response could be speculated to be counterproductive to 
clearance of infections but our study shows no difference in incidence of infections in the children. 
The study size limits the strength of this conclusion and these findings must be subject to further 
scrutiny in larger randomized control studies.  
Earlier studies on the protection of neonates by antenatal vaccination show that vaccination of the 
mother during pregnancy protects the infants against respiratory infections.
36–38
 Some studies 
propose a protection against Influenza virus due to passively transmitted antibodies
38
 while other 
studies propose a protection against Influenza morbidity caused by cocooning
36–38
. Yet other studies 
show the opposite and advocate an increased risk of respiratory infections in children of mothers 
vaccinated during pregnancy
24
 the latter may be in line with our immunological findings. 
A study of a population based cohort suggested that maternal influenza infection during pregnancy 
was associated with a twofold increased risk of infantile autism.
39
 Another study finds decreased 
neonatal levels of both Th-1 cytokines (i.e. IFN-γ) and Th-2 cytokines (i.e. IL-4, IL-10) in children 
later developing Autism Spectrum Disorders.
40
 Our results link these observations by showing that 
maternal influenza down-regulates the neonatal level of cytokines and chemokines. 
Conclusion 
This is the first study to assess airway immunology in neonates of mothers vaccinated during 
pregnancy, thereby presenting an unprecedented opportunity to explore the influence of antenatal 
vaccination on neonatal mucosal cytokine and chemokine immunology. Our findings suggest that 
H1N1pnd09 vaccination during pregnancy affects the mucosal immune competence of the unborn 
child and that this affect is dependent of time from birth of the vaccination.  
We observe a 1.6-fold increase in TGF-β1, along with decreased levels of the remaining immune 
mediators in upper airway of neonates from vaccinated mothers demonstrating that the fetal 
immune response is indeed affected by the maternal immune activation propagated by the 
vaccination protocol.  
This is a notable finding, underscoring the necessity for research into vaccination programs in 
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pregnant women and their influence on the neonatal immunity, not only focusing on neonatal 
immunity against the specific disease and the vaccine antigens, but the general immune status of the 
newborn child.     
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Abbreviations 
Th – T helper cells 
IFN-γ – Interferon-gamma 
IL – Interleukin 
TNF-α – Tumor necrosis factor-alpha 
Eotaxin-1 (CCL11) 
Eotaxin-3 (CCL26 ) 
IP-10 – Interferon gamma-induced protein 10 kDa (CXCL10) 
MCP-1  – Monocyte chemotactic protein 1 (CCL2) 
MCP-4 – Chemokine (CC-motif) ligand13 (CCL13) 
MDC – Macrophage-Derived Chemokine (CCL22) 
MIP-1β – Macrophage Inflammatory Protein-1β (CCL4) 
TARC – Thymus and Activation Regulated Chemokine (CCL17) 
TGF-β1 – Transforming Growth Factor beta 1 
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Tables and Figures 
Tables 
Table 1: Primary analysis of mediator levels in neonates born to mothers vaccinated during 
pregnancy versus  mediator levels in neonates born to mothers vaccinated after pregnancy.  
*Adjusted for season of birth, maternal atopy, older siblings, and bacterial colonization.  
’ False discovery rate <0.05 (Benjamini-Hochberg procedure for multiple testing correction) 
. Th-1 . Th-2 . Th17 . Treg . Lymphocyte expansion 
  Unadjusted Adjusted 
 Mediator Ratio[CI-low, CI-high] P-value * Ratio[CI-low, CI-high] P-value 
 IL-12p70 0.74[0.52, 1.04] P=0.08 0.62[0.40, 0.93] P=0.02 
 IP-10 0.92[0.54, 1.58] P=0.77 0.58[0.30, 1.11] P=0.10 
 IFN-γ 0.62[0.40, 0.97] P=0.04 0.33[0.19, 0.57] P=0.0001’ 
 TNF-α 1.04[0.60, 1.80] P=0.88 0.78[0.41, 1.46] P=0.43 
 MIP-1β 1.54[0.86, 2.73] P=0.14 0.95[0.50, 1.82] P=0.88 
  MCP-1 1.16[0.83, 1.62] P=0.39 0.83[0.54, 1.27] P=0.39 
  MCP-4 1.35[1.09, 1.67] P=0.006 1.27[0.97, 1.66] P=0.08 
 IL-4 0.75[0.49, 1.16] P=0.19 0.79[0.47, 1.34] P=0.38 
 IL-5 0.81[0.52, 1.26] P=0.35 0.49[0.30, 0.82] P=0.0073’ 
 IL-13 0.72[0.51, 1.00] P=0.05 0.77[0.51, 1.14] P=0.19 
 Eotaxin-1 0.97[0.72, 1.31] P=0.86 0.66[0.45, 0.97] P=0.04 
 Eotaxin-3 0.99[0.68, 1.46] P=0.98 0.72[0.44, 1.18] P=0.19 
 TARC 0.76[0.60, 0.97] P=0.03 0.54[0.40, 0.72] P=7.0∙10-5’ 
 MDC 0.63[0.46, 0.85] P=0.003 0.38[0.26, 0.54] P=4.8∙10-7’ 
 IL-17 1.48[0.75, 2.94] P=0.26 1.29[0.54, 3.10] P=0.56 
 IL-1β 0.81[0.41, 1.61] P=0.54 0.48[0.22, 1.04] P=0.06 
 IL-8 0.94[0.59, 1.52] P=0.81 0.56[0.32, 1.00] P=0.05 
 TGF-β1 1.38[1.16, 1.64] P=0.0004 1.52[1.22, 1.90] P=0.0002’ 
 IL-10 0.82[0.49, 1.36] P=0.44 0.71[0.40, 1.26] P=0.24 
 IL-2 1.09[0.71, 1.67] P=0.69 0.99[0.60, 1.64] P=0.97 
  
Table
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Table 2: Secondary analysis of mediator levels in neonates born to mothers vaccinated during 
pregnancy versus mediator levels in neonates of non-vaccinated controls.  
*Adjusted for participation in the randomized study, season of birth, maternal atopy, older siblings, 
and bacterial colonization.  
’ False discovery rate <0.05 (Benjamini-Hochberg procedure for multiple testing correction) 
. Th-1 . Th-2 . Th17 . Treg . Lymphocyte expansion 
  Unadjusted Adjusted 
 Mediator Ratio[CI-low, CI-high] P-value * Ratio[CI-low, CI-high] P-value 
 IL-12p70 0.95[0.68, 1.33] P=0.78 0.71[0.48, 1.03] P=0.07 
 IP-10 1.27[0.82, 1.96] P=0.28 0.88[0.52, 1.48] P=0.63 
 IFN-γ 1.13[0.73, 1.73] P=0.59 0.49[0.30, 0.81] P=0.005’ 
 TNF-α 1.10[0.70, 1.75] P=0.68 0.93[0.55, 1.58] P=0.80 
 MIP-1β 1.24[0.76, 2.01] P=0.39 1.14[0.66, 1.94] P=0.64 
  MCP-1 1.16[0.87. 1.55] P=0.31 1.07[0.75. 1.52] P=0.73 
  MCP-4 1.24[1.01. 1.51] P=0.04 1.19[0.94. 1.52] P=0.15 
 IL-4 0.70[0.47, 1.05] P=0.09 0.65[0.40, 1.05] P=0.08 
 IL-5 0.80[0.54, 1.18] P=0.26 0.56[0.36, 0.88] P=0.01 
 IL-13 0.82[0.60, 1.12] P=0.22 0.71[0.49, 1.03] P=0.07 
 Eotaxin-1 1.02[0.80, 1.30] P=0.86 0.90[0.67, 1.21] P=0.48 
 Eotaxin-3 1.34[0.93, 1.95] P=0.12 0.99[0.63, 1.55] P=0.97 
 TARC 1.02[0.81, 1.27] P=0.88 0.72[0.55, 0.94] P=0.02 
 MDC 1.14[0.87, 1.48] P=0.34 0.60[0.44, 0.82] P=0.001’ 
 IL-17 1.34[0.77, 2.35] P=0.30 1.22[0.63, 2.38] P=0.55 
 IL-1β 1.03[0.57, 1.87] P=0.92 0.63[0.32, 1.23] P=0.17 
 IL-8 1.34[0.91, 1.97] P=0.14 0.81[0.51, 1.28] P=0.36 
 TGF-β1 1.07[0.92, 1.25] P=0.35 1.32[1.11, 1.57] P=0.002’ 
 IL-10 0.93[0.63, 1.39] P=0.73 0.85[0.53, 1.35] P=0.49 
 IL-2 1.09[0.77, 1.54] P=0.63 1.10[0.73, 1.65] P=0.65 
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Table 3: Risk of infections in offspring during the first year of life 
Risk of infections  crude IRR[CI-low, CI-high] P-value  aIRR[CI-low, CI-high] P-value  
Vaccinated during pregnancy vs. after 
birth 
0.98[0.83;1.16] P=0.81 1.10[0.89;1.36]* P=0.37 
Vaccinated during pregnancy vs. non-
vaccinated controls 
1.00[0.86;1.15] P=0.95 0.99[0.84;1.18]‡ P=0.95 
*Adjusted for season of birth, maternal atopy, and older siblings.   
‡ Adjusted for season of birth, maternal atopy, older siblings, and participation in the randomized study. 
Confounding variables  crude IRR[CI-low, CI-high] P-value  
 
  
Older siblings 1.11[1.01;1.21] P=0.03 
 
  
Birth season (ref=Summer) 
 
  
 
  
Autumn 0.88[0.78;1.00] P=0.047 
 
  
Spring 1.02[0.89;1.17] P=0.77 
 
  
Winter 0.99[0.88;1.11] P=0.81 
 
  
Maternal Atopic Disease (yes/no) 1.02[0.93;1.11] P=0.70 
 
  
Participation in RCT 1.04[0.92;1.12] P=0.75     
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Figure 1: Ratios [95% confidence interval] between mean values of cytokine and chemokine , in 
the upper airway mucosal lining fluid in healthy neonates  of mothers vaccinated during pregnancy 
versus neonates born to mothers vaccinated after pregnancy. Data are adjusted for season of birth, 
maternal atopy, older siblings, and bacterial colonization. 
. Th-1 . Th-2 . Th17 . Treg . Lymphocyte expansion 
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Figure 2: TGF-β1 concentration vs. days from H1N1pnd09-vaccination  during pregnancy to 
sampling of mucosal lining fluid from the neonatal offspring. 
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Figure 3 Ratios [95% confidence interval] between mean values of cytokine and chemokine , in the 
upper airway mucosal lining fluid in healthy neonates  of mothers vaccinated during pregnancy 
versus neonates of non-vaccinated controls.  
All data is adjusted for participation in the randomized study, season of birth, maternal atopy, older 
siblings, and bacterial colonization. 
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Methods 
Time from vaccination to sampling of mucosal lining fluid: The time in days from vaccination to 
sampling of MLF was used as continues variable in the children born to mothers vaccinated during 
pregnancy. 
Season of birth: Date of birth was grouped into 4 seasons: winter (December-February), spring 
(March-May), summer (June-August) and fall (September-November).  
Older siblings at birth (yes/no): Children living in the home at the time of birth were considered as 
siblings.   
Bacterial colonization of the airway (yes/no): Aspiration from the hypopharyngeal area was done 
intermittently assuring no suction was applied during retraction through the oropharynx and 
nasopharynx. The catheter was flushed with 1 ml of saline into a vessel for remaining secretions 
from the tube. Samples were transported at room temperature to the microbiology laboratories 
within 24 hours at the Department of Microbiological Surveillance and Research, Statens Serum 
Institute in Copenhagen, Denmark. Colonization with Streptococcus pneumoniae, Hemophilus 
influenzae and/or Moraxella catarrhalis was considered as bacterial colonization with airway 
pathogenic bacteria.  
Maternal atopy (yes/no): Maternal atopic status was based on the history of doctor diagnosed 
asthma, hay fever and/or atopic dermatitis independent of sensitization.  
Supplemental Digital Content (Including Separate Legend)
Click here to download Supplemental Digital Content (Including Separate Legend): Supplemental Digital Content.docx 
Exposures during 3
rd
 trimester of pregnancy included smoking (yes/no), alcohol consumption 
(yes/no), and antibiotic usage (yes/no).  
Paternal atopy was defined from a history of doctor diagnosed asthma, hay fever and/or atopic 
dermatitis. (yes/no).  
Birth details comprised way of delivery (normal birth, planned or acute sectio); birth weight; 
gestational age; and Apgar score below or above four one minute after birth. 
Baseline antibody titers: Serum was sampled in the mothers prior to vaccination (baseline). Serum 
plasma levels of specific H1N1pnd09 antibodies were determined in twofold dilutions in a 
conventional hemagglutination-inhibition assay
39
. Geometric mean titers were computed from the 
log10-transformed mean. 
Socioeconomic status was evaluated from yearly household income at birth of the infant classified 
into five groups as <54·000 €; 54·000-81·000 €; 81·000-108·000 €; 108·000-135·000 €; and 
>135·000 €. 
  
Online Tables 
Table E1: Baseline characteristic of the study subjects 
 Vaccinated 
during pregnancy 
Vaccinated after 
birth 
Non-vaccinated 
Controls P-value 
N 51 105 332 
 
Sex (Male) %(n) 57(29) 53(56) 49(163) 0·52
F 
Birth weight, median(IQR) 3·6(3·3-3·9) 3·6(3·1-3·8) 3·5(3·2-4·0) 0·18
A
 
Gestational age, median(IQR) 40·0(39·4-40·9) 40·0(39·1-41·0) 40·1(39·0-41·1) 0·83
W 
Apgar (1 min) ≤4 %(n) 0 2(2) 2(8) 0·88F 
Mode of delivery     0·73
F
 
    Normal 80(41) 73(77) 78(259)  
    Planned sectio 8(4) 11(12) 11(37)  
    Acute sectio 12(6) 15(16) 11(36)  
Season of birth    3·2*10
-24, F 
    Spring 14(7) 10(11) 20(65)  
    Summer 12(6) 59(62) 21(69)  
    Fall 29(15) 30(32) 20(66)  
    Winter 45(23) 0 40(132)  
 Airway bacteria* (4 week)%(n) 28(14) 21(22) 32(106) 0·09
F
 
Older siblings %(n) 51(26) 65(68) 61(201) 0·26
F
 
Baseline antibody titer, GMT(CI) 11(8-15) 13(11-17) - 0·29
 A
 
Antibiotics (3
rd
 trim) %(n) 24(12) 16(17) 21(69) 0·47
F
 
Smoking (3
rd
 trim) %(n) 8(4) 4(4) 4(13) 0·44
F
 
Alcohol  (3
rd
 trim) %(n) 6(3) 7(7) 3(11) 0·23
F
 
Income (pr. year) %(n)    0·57
F
 
    <54·000 €  8(4) 13(14) 9(29)  
    54·000-134·000 € 80(41) 79(83) 80(263)  
    >134·000 € 12(6) 8(8) 11(37)  
Mothers age, median(IQR) 32·5(29·5-35·5) 32·0(29·4-35·6) 31·7(29·0-35·0) 0·45
A 
Maternal atopy %(n) 39(20) 48(50) 55(181) 0·07
F
 
Paternal atopy %(n) 38(18) 46(47) 46(147) 0·52
F
 
IQR: Inter Quartile Range 
GMT: Geometric Mean Titer 
FFisher’s exact test 
W
Wilcoxon Rank sum test 
A
Anova 
*Airway colonization with at least one of: M. Catharalis, H. Influenza, S. Pneumonia 
 
  
Table E2: Univariate analysis of association between mucosal lining fluid mediator levels and time 
in days from H1N1pnd09-vaccination with to sampling of mucosal lining fluid. 
*Adjusted for season of birth, maternal atopy, older siblings, and bacterial colonization.  
’ False discovery rate <0·05 (Benjamini-Hochberg procedure for multiple testing correction) 
• Th-1   • Th-2   • Th17   • Treg   • Lymphocyte expansion 
  
 
Unadjusted Adjusted 
  
Mediator  [CI-low, CI-high] P-value 
*[CI-low, CI-high] P-
value 
  IL-12p70 [0·98, 1·00] P=0·07 [0·98, 1·00] P=0·16 
  IP-10 [0·98, 1·00] P=0·03 [0·97, 1·00] P=0·08 
  IFN-γ [0·98, 1·00] P=0·05 [0·98, 1·00] P=0·17 
  TNF-α [0·98, 1·00] P=0·15 [0·98, 1·01] P=0·37 
  MIP-1β [0·97, 1·00] P=0·07 [0·98, 1·01] P=0·36 
  MCP-1 [0·99, 1·00] P=0·24 [0·99, 1·01] P=0·84 
  MCP-4 [1·00, 1·01] P=0·72 [1·00, 1·01] P=0·58 
  IL-4 [0·99, 1·01] P=0·63 [0·99, 1·01] P=0·89 
  IL-5 [0·97, 0·99] P=0·001’ [0·97, 1·00] P=0·01 
  IL-13 [0·99, 1·00] P=0·18 [0·98, 1·00] P=0·09 
  Eotaxin-1 [0·99, 1·00] P=0·10 [0·99, 1·01] P=0·64 
  Eotaxin-3 [0·98, 1·00] P=0·01’ [0·98, 0·99] P=0·003’ 
  TARC [0·99, 1·00] P=0·03 [0·99, 1·00] P=0·05 
  MDC [0·98, 1·00] P=0·01’ [0·98, 1·00] P=0·02 
  IL-17 [0·98, 1·01] P=0·25 [0·98, 1·01] P=0·62 
  IL-1β [0·98, 1·01] P=0·21 [0·98, 1·01] P=0·67 
  IL-8 [0·98, 1·00] P=0·03 [0·98, 1·01] P=0·35 
  TGF-β1 [1·00, 1·01] P=0·0004’ [1·00, 1·01] P=0·0003’ 
  IL-10 [0·98, 1·00] P=0·03 [0·97, 1·00] P=0·01 
  IL-2 [0·99, 1·00] P=0·30 [0·99, 1·01] P=0·76 
 
  
Online Figures 
Figure E1:  Flowchart of study participants 
332children of 
mothers receiving 
no vaccination
743 women 
included in pregnancy cohort
700 children 
included in birth cohort
12 Mothers vaccinated ≤ 4 weeks after birth
(before MLF sampling)
51 children of 
mothers vaccinated 
during pregnancy
105 children of 
mothers vaccinated ≥ 
4 weeks after birth
43 dropouts
367 children of 
mothers receiving 
no vaccination
564 Children eligible for study
124 Mothers received other H1N1
34 did not have 
MLF sampled 
7 did not have 
MLF sampled 
58 children of 
mothers vaccinated 
during pregnancy
139 children of 
mothers vaccinated ≥ 
4 weeks after birth
35 did not have 
MLF sampled
49 children 
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103 children 
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284 children 
returned dairy cards
 
  
Figure E2: IL-5 concentration vs. days from H1N1pnd09-vaccination  during pregnancy to 
sampling of mucosal lining fluid from the neonatal offspring. 
 
